about
Changes in second-line regimen durability and continuity of care in relation to national ART guideline changes in South AfricaIncidence and predictors of herpes zoster among antiretroviral therapy-naïve patients initiating HIV treatment in Johannesburg, South AfricaThe relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa.The impact of choice of NNRTI on short-term treatment outcomes among HIV-infected patients prescribed tenofovir and lamivudine in Johannesburg, South Africa.Marginal Structural Models to Assess Delays in Second-Line HIV Treatment Initiation in South Africa.Early Outcomes Of Decentralized Care for Rifampicin-Resistant Tuberculosis in Johannesburg, South Africa: An Observational Cohort StudyPredictive and prognostic properties of TB-LAM among HIV-positive patients initiating ART in Johannesburg, South Africa.Developing a predictive risk model for first-line antiretroviral therapy failure in South AfricaCan Short-Term Use of Electronic Patient Adherence Monitoring Devices Improve Adherence in Patients Failing Second-Line Antiretroviral Therapy? Evidence from a Pilot Study in Johannesburg, South Africa.Treatment outcomes of over 1000 patients on second-line, protease inhibitor-based antiretroviral therapy from four public-sector HIV treatment facilities across Johannesburg, South Africa.Missed appointments among rifampicin-resistant tuberculosis (RR-TB) patients at a decentralised RR-TB outpatient clinic in Johannesburg, South Africa.Adverse drug reactions during drug-resistant TB treatment in high HIV prevalence settings: a systematic review and meta-analysis.Does disseminated nontuberculous mycobacterial disease cause false-positive Determine B-LAM lateral flow assay results? A retrospective review.Persistently high early mortality despite rapid diagnostics for drug-resistant tuberculosis cases in South Africa.Treatment initiation among persons diagnosed with drug resistant tuberculosis in Johannesburg, South Africa.Incident tuberculosis in HIV-positive children, adolescents and adults on antiretroviral therapy in South Africa.Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South Africa.Outcomes of TB/HIV co-infected patients presenting with antituberculosis drug-induced liver injury.A call to action: Addressing the reproductive health needs of women with drug-resistant tuberculosis.Predictors of mortality and treatment success during treatment for rifampicin-resistant tuberculosis within the South African National TB Programme, 2009 to 2011: a cohort analysis of the national case register.Direct costs of managing adverse drug reactions during rifampicin-resistant tuberculosis treatment in South Africa.Performance of Xpert MTB/RIF, Xpert Ultra, and Abbott Real Tie MTB for the diagnosis of pulmonary tuberculosis in a high HIV burden settingHigh rates of death and loss to follow-up by 12 months of rifampicin resistant TB treatment in South AfricaDiscordant rifampicin susceptibility results are associated with Xpert MTB/RIF probe B and probe binding delayThe impact of adverse events on health-related quality of life among patients receiving treatment for drug-resistant tuberculosis in Johannesburg, South Africa.Treatment outcomes among children, adolescents, and adults on treatment for tuberculosis in two metropolitan municipalities in Gauteng Province, South AfricaCost outcome analysis of decentralized care for drug-resistant tuberculosis in Johannesburg, South Africa
P50
Q33777513-DE9402AD-2508-4A36-991F-67A0A46AC2DEQ33883111-84B90566-112E-4B78-ACF4-FD18EFE8CF50Q34433397-3DEB11AB-05FF-4B8B-835A-F8758C5760BEQ34938054-537D3871-D1F7-4B68-A5F8-158A6227A9C9Q36109276-FB048B1F-0B1A-4A42-9A40-38442AA78267Q36182135-B321AA6C-E735-45D8-B868-F1A7DF5EF86FQ36275193-140F3701-78E2-4EED-B842-A434D48DE814Q37290134-DEE3C83D-F707-499A-8616-4BBA64A9BA85Q37348464-BD41DEAE-3406-4752-927F-5E4126287A25Q37619925-D758FAA4-C0C6-426F-942E-9ACFADC5BAB4Q38947916-CCCBC9BF-09DD-4B26-BA30-5D1F2D92F394Q39248451-DD2D036D-44BA-4D3F-B83A-3337D48C233BQ39346385-7D3DA50D-98B6-417D-9BD7-9E26C7D524D4Q40040620-91670417-EE3F-4215-8946-B47A1735B9B0Q40107565-23E0E2DD-A327-4AFA-83B0-4F74A6F09226Q40620262-110C8086-407F-4D10-9913-66B3F0C50F14Q40623733-A5C2749B-12E4-4154-8037-6A92DA2D6E7AQ40660717-5DB4283D-4605-4CD4-A4CF-BD7A26590AB2Q40733716-10191C7E-BA02-4FAC-8ECA-993D4C6A344CQ41006045-B4D2E5FF-6A46-4399-B1DB-28E0673B8196Q52644273-83E05993-944E-435C-BC34-90CE2C7E765BQ57284525-B20FAD12-B872-4864-9F78-2914BF014480Q57291999-F4A03F34-A749-43FD-8FA1-61B2DC333C94Q64079124-783271F0-D4AF-4D8E-BE4D-641AD2233E68Q64905489-A68A82D6-5542-43B0-BED2-DE0ED24E4688Q92085938-133A41D4-154F-441E-AFF1-3F4F8354FC93Q92562586-D0C0A4CE-9191-4F5D-A312-D4CF115169AC
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Rebecca Berhanu
@ast
Rebecca Berhanu
@en
Rebecca Berhanu
@es
Rebecca Berhanu
@nl
Rebecca Berhanu
@sl
type
label
Rebecca Berhanu
@ast
Rebecca Berhanu
@en
Rebecca Berhanu
@es
Rebecca Berhanu
@nl
Rebecca Berhanu
@sl
prefLabel
Rebecca Berhanu
@ast
Rebecca Berhanu
@en
Rebecca Berhanu
@es
Rebecca Berhanu
@nl
Rebecca Berhanu
@sl
P106
P21
P31
P496
0000-0002-9692-8748